Compare HWH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWH | GDTC |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 10.4M |
| IPO Year | 2022 | 2021 |
| Metric | HWH | GDTC |
|---|---|---|
| Price | $1.81 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 44.4K | 42.3K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $866,926.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.68 |
| 52 Week High | $7.77 | $3.68 |
| Indicator | HWH | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 67.91 | 38.21 |
| Support Level | $0.97 | $0.71 |
| Resistance Level | $1.81 | $1.09 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 81.51 | 20.40 |
HWH International Inc and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore. The Company is presently developing Hapi Marketplace, a business-to-consumer platform featuring diverse product categories, and Hapi Wealth Builder, an educational program focused on wealth-building strategies.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.